Enanta Pharmaceuticals Will Provide An Update Across Its Pipeline And Plans For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference On Wednesday, January 10, 2024
- Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024
- Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season
- Anticipate Challenge Study Data for EDP-323, an L-Protein Inhibitor in Development to Treat RSV, in 3Q 2024